Four failure patterns, and how to design them out

Why Data & AI Portfolios Stall in Regulated Environments

A portfolio governance model for regulated environments: intake funnel, decision rights, benefit ownership, and the move into business-as-usual

Read more
filters
AI Transformation
Portfolio Governance
The Context

Most data and AI portfolios do not fail because the technology does not work. They fail because no forum was ever obliged to choose.Trade-offs surfaced, and nobody had to resolve them.

Capacity is the binding constraint. Good ideas are plentiful; what runs short is the specific people who can move an idea through a regulated organisation and into stable operations – the ones who clear data access, validation evidence, and privacy review.

Approve work without accounting for that, and the portfolio becomes over-committed. Nothing fails outright. Initiatives drift, teams fragment, and the slippage becomes visible only once it is too late to trade anything off.

While this is written from a pharma and life sciences PoV, the patterns recur wherever validation, privacy, and quality sit on the critical path.

The Context

Most data and AI portfolios do not fail because the technology does not work. They fail because no forum was ever obliged to choose.Trade-offs surfaced, and nobody had to resolve them.

Capacity is the binding constraint. Good ideas are plentiful; what runs short is the specific people who can move an idea through a regulated organisation and into stable operations – the ones who clear data access, validation evidence, and privacy review.

Approve work without accounting for that, and the portfolio becomes over-committed. Nothing fails outright. Initiatives drift, teams fragment, and the slippage becomes visible only once it is too late to trade anything off.

While this is written from a pharma and life sciences PoV, the patterns recur wherever validation, privacy, and quality sit on the critical path.

The Context

Most data and AI portfolios do not fail because the technology does not work. They fail because no forum was ever obliged to choose.Trade-offs surfaced, and nobody had to resolve them.

Capacity is the binding constraint. Good ideas are plentiful; what runs short is the specific people who can move an idea through a regulated organisation and into stable operations – the ones who clear data access, validation evidence, and privacy review.

Approve work without accounting for that, and the portfolio becomes over-committed. Nothing fails outright. Initiatives drift, teams fragment, and the slippage becomes visible only once it is too late to trade anything off.

While this is written from a pharma and life sciences PoV, the patterns recur wherever validation, privacy, and quality sit on the critical path.

The Context

Most data and AI portfolios do not fail because the technology does not work. They fail because no forum was ever obliged to choose.Trade-offs surfaced, and nobody had to resolve them.

Capacity is the binding constraint. Good ideas are plentiful; what runs short is the specific people who can move an idea through a regulated organisation and into stable operations – the ones who clear data access, validation evidence, and privacy review.

Approve work without accounting for that, and the portfolio becomes over-committed. Nothing fails outright. Initiatives drift, teams fragment, and the slippage becomes visible only once it is too late to trade anything off.

While this is written from a pharma and life sciences PoV, the patterns recur wherever validation, privacy, and quality sit on the critical path.

The Context

Most data and AI portfolios do not fail because the technology does not work. They fail because no forum was ever obliged to choose.Trade-offs surfaced, and nobody had to resolve them.

Capacity is the binding constraint. Good ideas are plentiful; what runs short is the specific people who can move an idea through a regulated organisation and into stable operations – the ones who clear data access, validation evidence, and privacy review.

Approve work without accounting for that, and the portfolio becomes over-committed. Nothing fails outright. Initiatives drift, teams fragment, and the slippage becomes visible only once it is too late to trade anything off.

While this is written from a pharma and life sciences PoV, the patterns recur wherever validation, privacy, and quality sit on the critical path.

The Context

Four Patterns We See Repeatedly
  1. Three initiatives approved in a quarter, all depending on the same two data engineers and the same validation queue. Each approval was sound on its own merits. The portfolio was never actually decided.
  2. Green for six consecutive weeks, then a single-step slip. Nobody is rewarded for escalating early, so the status holds while the assumptions underneath it drift.
  3. A solution the users call a success, the people funding it call unproven.
  4. Monitoring in place and alerts accumulating unread. Accountability for the outcome, the service, and the data definitions all defaulted to the last project team standing.
Four Patterns We See Repeatedly
  1. Three initiatives approved in a quarter, all depending on the same two data engineers and the same validation queue. Each approval was sound on its own merits. The portfolio was never actually decided.
  2. Green for six consecutive weeks, then a single-step slip. Nobody is rewarded for escalating early, so the status holds while the assumptions underneath it drift.
  3. A solution the users call a success, the people funding it call unproven.
  4. Monitoring in place and alerts accumulating unread. Accountability for the outcome, the service, and the data definitions all defaulted to the last project team standing.
Four Patterns We See Repeatedly
  1. Three initiatives approved in a quarter, all depending on the same two data engineers and the same validation queue. Each approval was sound on its own merits. The portfolio was never actually decided.
  2. Green for six consecutive weeks, then a single-step slip. Nobody is rewarded for escalating early, so the status holds while the assumptions underneath it drift.
  3. A solution the users call a success, the people funding it call unproven.
  4. Monitoring in place and alerts accumulating unread. Accountability for the outcome, the service, and the data definitions all defaulted to the last project team standing.

Four Patterns We See Repeatedly

  1. Three initiatives approved in a quarter, all depending on the same two data engineers and the same validation queue. Each approval was sound on its own merits. The portfolio was never actually decided.
  2. Green for six consecutive weeks, then a single-step slip. Nobody is rewarded for escalating early, so the status holds while the assumptions underneath it drift.
  3. A solution the users call a success, the people funding it call unproven.
  4. Monitoring in place and alerts accumulating unread. Accountability for the outcome, the service, and the data definitions all defaulted to the last project team standing.

Four Patterns We See Repeatedly

  1. Three initiatives approved in a quarter, all depending on the same two data engineers and the same validation queue. Each approval was sound on its own merits. The portfolio was never actually decided.
  2. Green for six consecutive weeks, then a single-step slip. Nobody is rewarded for escalating early, so the status holds while the assumptions underneath it drift.
  3. A solution the users call a success, the people funding it call unproven.
  4. Monitoring in place and alerts accumulating unread. Accountability for the outcome, the service, and the data definitions all defaulted to the last project team standing.

Four Patterns We See Repeatedly

What You'll Discover in the Whitepaper
  1. A two-lane intake funnel, with a fast-track for mandatory work
  2. Decision rights split across Decision Board, Steering Committee, and operational reporting
  3. Three separate funding models for different business realities
  4. A benefit framework covering financial, capacity, and risk/quality outcomes, with worked kill triggers
  5. A five-point handover checklist for the move into business-as-usual
What You'll Discover in the Whitepaper
  1. A two-lane intake funnel, with a fast-track for mandatory work
  2. Decision rights split across Decision Board, Steering Committee, and operational reporting
  3. Three separate funding models for different business realities
  4. A benefit framework covering financial, capacity, and risk/quality outcomes, with worked kill triggers
  5. A five-point handover checklist for the move into business-as-usual
What You'll Discover in the Whitepaper
  1. A two-lane intake funnel, with a fast-track for mandatory work
  2. Decision rights split across Decision Board, Steering Committee, and operational reporting
  3. Three separate funding models for different business realities
  4. A benefit framework covering financial, capacity, and risk/quality outcomes, with worked kill triggers
  5. A five-point handover checklist for the move into business-as-usual

What You'll Discover in the Whitepaper

  1. A two-lane intake funnel, with a fast-track for mandatory work
  2. Decision rights split across Decision Board, Steering Committee, and operational reporting
  3. Three separate funding models for different business realities
  4. A benefit framework covering financial, capacity, and risk/quality outcomes, with worked kill triggers
  5. A five-point handover checklist for the move into business-as-usual

What You'll Discover in the Whitepaper

  1. A two-lane intake funnel, with a fast-track for mandatory work
  2. Decision rights split across Decision Board, Steering Committee, and operational reporting
  3. Three separate funding models for different business realities
  4. A benefit framework covering financial, capacity, and risk/quality outcomes, with worked kill triggers
  5. A five-point handover checklist for the move into business-as-usual

What You'll Discover in the Whitepaper

Why It Matters

All of these concepts are familiar, and most portfolios already run two or three of them well. The difficulty is that the value sits in the sequence. Intake decides what enters. Governance decides what stops. The value framework supplies evidence for both. The handover decides who is still accountable when that evidence arrives. Break the chain at any point, and the portfolio quietly reverts to drift.

Why It Matters

All of these concepts are familiar, and most portfolios already run two or three of them well. The difficulty is that the value sits in the sequence. Intake decides what enters. Governance decides what stops. The value framework supplies evidence for both. The handover decides who is still accountable when that evidence arrives. Break the chain at any point, and the portfolio quietly reverts to drift.

Why It Matters

All of these concepts are familiar, and most portfolios already run two or three of them well. The difficulty is that the value sits in the sequence. Intake decides what enters. Governance decides what stops. The value framework supplies evidence for both. The handover decides who is still accountable when that evidence arrives. Break the chain at any point, and the portfolio quietly reverts to drift.

Why It Matters

All of these concepts are familiar, and most portfolios already run two or three of them well. The difficulty is that the value sits in the sequence. Intake decides what enters. Governance decides what stops. The value framework supplies evidence for both. The handover decides who is still accountable when that evidence arrives. Break the chain at any point, and the portfolio quietly reverts to drift.

Why It Matters

All of these concepts are familiar, and most portfolios already run two or three of them well. The difficulty is that the value sits in the sequence. Intake decides what enters. Governance decides what stops. The value framework supplies evidence for both. The handover decides who is still accountable when that evidence arrives. Break the chain at any point, and the portfolio quietly reverts to drift.

Why It Matters

Whitepaper

The whitepaper breaks down the full governance model: intake and prioritization criteria, decision rights, funding models, a value framework covering financial, capacity, and risk outcomes, and the kill triggers that let leaders stop work without stigma.

Curious how this applies to your own portfolio?

Reach out to our team - we're happy to talk it through. We've worked with organizations on these same governance gaps in data and AI portfolios, and can help you spot where yours might be exposed.

Manager
Silas Faurschou

Manager
Silas Faurschou
Silas Faurschou
This is the default text value
Head of Strategy & Transformation
Dan Nielsen

Head of Strategy & Transformation
Dan Nielsen
Dan Nielsen
This is the default text value
filters
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Global to Local Content Excellence

In this article we give our point of view on how healthcare organizations can design a scalable content engine with local flexibility for impactful customer engagement - and how to succeed where other organizations typically fail.

Click to read more
Content Excellence
Global to Local Content Excellence
Global to Local Content Excellence
Customer Engagement & Experience
Personalization at Scale
The Build vs Buy Dillemma: Balancing correctness and differentiation in enterprise AI

In this perspective on Build vs Buy in AI, we share how to move beyond a buy-only mindset by designing AI around your processes and competitive edge. We explore why off-the-shelf works well in domains where correctness and compliance matter most, why you need more ownership in use cases that drive differentiation, and how a hybrid approach - buying the base and building the system around it - keeps operations stable while still enabling you to stand out.

Click to read more
AI STRATEGY
The Build vs Buy Dillemma
The Build vs Buy Dillemma
AI Transformation
Mastering CX in Pharma: Designing Your Future HCP Engagement Model

In this four-part series, “Mastering CX in Pharma”, we aim to share our perspective and approaches on how to succeed in designing a winning customer experience. We will deep dive into engagement model design, data as a key enabler, how to design an operating model that supports your strategic ambitions, and the role of change management.

Click to read more
Customer Experience in Pharma
Mastering CX in Pharma (Part 1)
Mastering CX in Pharma (Part 1)
Personalization at Scale
Customer Engagement & Experience
AI Transformation
Mastering CX in Pharma: Why Data is the Backbone for Success

In this four-part series, “Mastering CX in Pharma”, we aim to share our perspective and approaches on how to succeed in designing a winning customer experience. We will deep dive into engagement model design, data as a key enabler, how to design an operating model that supports your strategic ambitions, and the role of change management.

Click to read more
Customer Experience in Pharma
Mastering CX in Pharma (Part 2)
Mastering CX in Pharma (Part 2)
Customer Engagement & Experience
AI Transformation
Personalization at Scale